Pub Date : 2023-01-01DOI: 10.1358/dof.2023.48.2.3400571
M. Ahmad, A. Dasgupta, S. Chopra
{"title":"Ancremonam. Monobactam, Treatment of multidrug-resistant Enterobacteriaceae infections","authors":"M. Ahmad, A. Dasgupta, S. Chopra","doi":"10.1358/dof.2023.48.2.3400571","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3400571","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1358/dof.2023.48.2.3542401
J. Toldrà
{"title":"Society for Immunotherapy of Cancer (SITC) - 37th Annual Meeting. Boston/Virtual - November 8-12, 2022","authors":"J. Toldrà","doi":"10.1358/dof.2023.48.2.3542401","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3542401","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1358/dof.2023.48.2.3542442
M. Alavijeh, D. Black, G. Macdonald
{"title":"Innovative new pharma and biotech partnerships: How is the landscape transforming? Highlights from the Society for Medicines Research Conference. Stevenage - July 7, 2022","authors":"M. Alavijeh, D. Black, G. Macdonald","doi":"10.1358/dof.2023.48.2.3542442","DOIUrl":"https://doi.org/10.1358/dof.2023.48.2.3542442","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66447040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.6.3444838
L. Fernández Bertolín
{"title":"Pipeline on the Move - June 2022","authors":"L. Fernández Bertolín","doi":"10.1358/dof.2022.47.6.3444838","DOIUrl":"https://doi.org/10.1358/dof.2022.47.6.3444838","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.10.3447918
L. Ferro Desideri, S. Vaccaro, A. Vagge, M. Nicolò, V. Scorcia, C. Traverso, G. Giannaccare
{"title":"RGX-314. AAV8 gene therapy encoding anti-VEGF Fab, Treatment of wet age-related macular degeneration, \u0000Treatment of diabetic retinopathy","authors":"L. Ferro Desideri, S. Vaccaro, A. Vagge, M. Nicolò, V. Scorcia, C. Traverso, G. Giannaccare","doi":"10.1358/dof.2022.47.10.3447918","DOIUrl":"https://doi.org/10.1358/dof.2022.47.10.3447918","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66440604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.1.3369190
B. Warden, P. Duell
{"title":"Pelacarsen. Antisense oligonucleotide targeting apolipoprotein(a), Treatment of lipoprotein disorders, Treatment of cardiovascular diseases","authors":"B. Warden, P. Duell","doi":"10.1358/dof.2022.47.1.3369190","DOIUrl":"https://doi.org/10.1358/dof.2022.47.1.3369190","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66440872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.11.3435134
A. Moreno-Castaño, G. Escolar, M. Díaz-Ricart
In 2020, a coronavirus-related disease (COVID-19) became a pandemic. The disease was recognized as a viral respiratory illness caused by SARS-CoV-2. Histologic analysis of pulmonary vessels in severely affected patients revealed a microangio-pathic thrombosis. It was rapidly recognized that the disease could behave as a thrombotic disease, both in the venous and arterial circulations and affecting multiple organs. Anticoa-gulant treatments were immediately considered to prevent or control the underlying coagulopathy. The emergency of the situation and the limited knowledge in the early months accounted for variable success of the anticoagulation regi-mens. The benefit/bleeding risk ratio of anticoagulant treat-ments depended on the severity and evolution of the disease in different subgroups of patients. This review aims to provide a synthesized guide on how anticoagulant protocols indicated for the prophylaxis and treatment of COVID-19-related hyper -coagulable state have evolved and have been successfully adapted to specific scenarios throughout the pandemic.
{"title":"An overview of prophylaxis and treatment indications for COVID-19-related thrombotic complications. Review of the recent literature","authors":"A. Moreno-Castaño, G. Escolar, M. Díaz-Ricart","doi":"10.1358/dof.2022.47.11.3435134","DOIUrl":"https://doi.org/10.1358/dof.2022.47.11.3435134","url":null,"abstract":"In 2020, a coronavirus-related disease (COVID-19) became a pandemic. The disease was recognized as a viral respiratory illness caused by SARS-CoV-2. Histologic analysis of pulmonary vessels in severely affected patients revealed a microangio-pathic thrombosis. It was rapidly recognized that the disease could behave as a thrombotic disease, both in the venous and arterial circulations and affecting multiple organs. Anticoa-gulant treatments were immediately considered to prevent or control the underlying coagulopathy. The emergency of the situation and the limited knowledge in the early months accounted for variable success of the anticoagulation regi-mens. The benefit/bleeding risk ratio of anticoagulant treat-ments depended on the severity and evolution of the disease in different subgroups of patients. This review aims to provide a synthesized guide on how anticoagulant protocols indicated for the prophylaxis and treatment of COVID-19-related hyper -coagulable state have evolved and have been successfully adapted to specific scenarios throughout the pandemic.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66440996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1358/dof.2022.47.11.3400746
D. Saxena, A. Dasgupta, S. Chopra
{"title":"Xeruborbactam. Ultrabroad-spectrum beta-lactamase inhibitor, Treatment of bacterial infections","authors":"D. Saxena, A. Dasgupta, S. Chopra","doi":"10.1358/dof.2022.47.11.3400746","DOIUrl":"https://doi.org/10.1358/dof.2022.47.11.3400746","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66441369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：